Evidence map›Paper›PMID 34189639›Full record

ArticlePharmaceutical research2021

Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.

Hongtao Xu, Yan Li, James W Paxton, Zimei Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hongtao XuSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Yan LiDepartment of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
James W PaxtonDepartment of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Zimei WuSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. z.wu@auckland.ac.nz.ORCID http://orcid.org/0000-0001-9777-0674
University of Auckland · NZ

Funding

Auckland Medical Research Foundation 1113026Marsden Fund UOA1201
6 · The paper itself

Abstract

purposePEGylated pH-sensitive liposomes (PSL) dual-loaded with gemcitabine and curcumin were investigated for the potential application in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) treatment. Curcumin was employed as an inhibitor of the efflux transporter, multidrug resistance protein 5 (MRP5) in PDAC cells.

methodsLiposomes were prepared with gemcitabine in the core and curcumin in the bilayers. The effects of curcumin on pH-sensitivity and 'endosome escape' of PSL with different PEGylation were investigated using a calcein self-quench assay. The effects of curcumin on intracellular gemcitabine concentrations, and cytotoxicity to a MIA PaCa-2 PDAC cell line was evaluated. The pharmacokinetics were investigated in rats following intravenous injection.

resultsThe addition of curcumin to the PSL bilayers (0.2-1 mol%)slightly decreased the pH-sensitivity of PSL, but to a less extent than PEGylation (0-5 mol%). Co-treatment with curcumin increased gemcitabine cellular accumulation in a concentration-dependent manner, and resulted in synergistic cytotoxicity towards MIA PaCa-2cells.Both these effects were augmented by the use of PSL, particularly when the two drugs were co-loaded in PSL. In rats, the dual-drug loaded PSL produced significantly reduced (p < 0.05) plasma clearance (CL) and volume of distribution (V

conclusionCo-delivery of curcumin with gemcitabine using PSL not only increased the intracellular gemcitabine concentration thus cytotoxicity to MIA PaCa-2 cells but also significantly improved the pharmacokinetic profiles for both drugs. Graphical Abstract.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveATP-Binding Cassette, Sub-Family C ProteinsCarcinoma, Pancreatic DuctalCell Line, TumorCurcuminDeoxycytidineDrug LiberationDrug Resistance, NeoplasmDrug SynergismGemcitabineHumansHydrogen-Ion ConcentrationLiposomesMaleABCC5 protein, humanATP-Binding Cassette, Sub-Family C ProteinsCurcuminDeoxycytidineGemcitabineLiposomesmonomethoxypolyethylene glycolPolyethylene Glycolscurcumincytotoxicitydual drug loaded liposomesefflux transportergemcitabinepharmacokinetics

Identifiers

PMID34189639
OpenAlexW3177114147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.